Prime Therapeutics' leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years News provided by Prime Therapeutics LLC Jun 25, 2025, 10:00 ET Findings also show improved persistence with high-potency, obesity-approved GLP-1 products EAGAN, Minn., June 25, 2025 /PRNewswire/ -- Only 8% of individuals (or 1 in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to do so at three years, according to the latest real-world research from pharmacy solutions partner Prime Therapeutics LLC (Prime)
For more information, readpackage insert
Other Ingredients: Purified Water, L-Glutathione, Glycerine, Glyceryl Dilaurate, Cetearyl Alcohol, Glyceryl Stearate, PEG-100 Stearate, Ceteareth-20, Isopropyl Myristate, Guar Gum, Imidurea NF, Methyl Paraben, Propyl Paraben Free Of: Milk, Eggs, Fish, Shellfish, Peanuts, and Wheat
This is going to be a constant disclaimer on this site, but please understand I am not a doctor and especially where benzos are consideredyes, the scaremongers are correct and it can kill you to withdraw improperlyyou really must consult with a professional who can at least weigh in on whether any of this could work for you
Because of national shortages of brand-name pens, our clinic provides high-quality compounded Tirzepatide, prepared in FDA-regulated pharmacies, offering the exact same active ingredient to give you superior control over hunger and metabolism
Although a dual agonist capable of activating both GLP1R and GIPR , Tirzepatide preferentially activates GIPR more, over GLP1R
.webp)
